0001209191-14-077751.txt : 20141223 0001209191-14-077751.hdr.sgml : 20141223 20141223162528 ACCESSION NUMBER: 0001209191-14-077751 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141223 FILED AS OF DATE: 20141223 DATE AS OF CHANGE: 20141223 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001358403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 850 CITY: HOUSTON STATE: TX ZIP: 77030 BUSINESS PHONE: (832) 384-1100 MAIL ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 850 CITY: HOUSTON STATE: TX ZIP: 77030 FORMER COMPANY: FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Remeditex Ventures LLC CENTRAL INDEX KEY: 0001627363 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36783 FILM NUMBER: 141307205 BUSINESS ADDRESS: STREET 1: 2101 CEDAR SPRINGS ROAD, SUITE 601 CITY: DALLAS STATE: TX ZIP: 75201 BUSINESS PHONE: (214) 506-2662 MAIL ADDRESS: STREET 1: 2101 CEDAR SPRINGS ROAD, SUITE 601 CITY: DALLAS STATE: TX ZIP: 75201 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-12-23 0 0001358403 BELLICUM PHARMACEUTICALS, INC BLCM 0001627363 Remeditex Ventures LLC 2101 CEDAR SPRINGS ROAD, SUITE 601 DALLAS TX 75201 0 0 1 0 Common Stock 2014-12-23 4 C 0 1359297 A 1359297 D Common Stock 2014-12-23 4 C 0 159444 A 1518741 D Common Stock 2014-12-23 4 C 0 245299 A 1764040 D Common Stock 2014-12-23 4 J 0 43563 0.00 A 1807603 D Series B Convertible Preferred Stock 2014-12-23 4 C 0 2310806 0.00 D Common Stock 1359297 0 D Series C Convertible Preferred Stock 2014-12-23 4 C 0 271055 0.00 D Common Stock 159444 0 D Series C Convertible Preferred Stock 2014-12-23 4 C 0 417009 0.00 D Common Stock 245299 0 D The Series B Convertible Participating Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date. Reflects 1.7-for-1 reverse stock split which became effective on December 5, 2014. The Series C Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date. On December 4, 2014, the Board of Directors of the Issuer declared a dividend payable to all holders of records of the Series B Convertible Participating Preferred Stock of the Issuer on December 16, 2014, payable in the form of cash or in shares of Common Stock of the Issuer, at the option of each holder. The dividends occurred in connection with the closing of the Issuer's public offering. The Reporting Person elected to receive the shares of Common Stock. By: /s/ John Creecy, CEO 2014-12-23